3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
7
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
41
Carcinoma, Renal Cell
32
Neuroendocrine Tumors
15
Neoplasms
12
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
8
Carcinoma
7
Tuberous Sclerosis
6
Kidney Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoid Tumor
5
Lymphoma
4
Adenoma, Islet Cell
4
Stomach Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell
3
Lymphangioleiomyomatosis
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Angiomyolipoma
3
Adenocarcinoma
3
von Hippel-Lindau Disease
2
Triple Negative Breast Neoplasms
2
Seizures
2
Neuroectodermal Tumors, Primitive
2
Lymphoproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Interventions
pembrolizumab
44
Paclitaxel
37
Carboplatin
30
Doxorubicin
11
Cisplatin
11
Bevacizumab
11
lenvatinib
9
Nivolumab
9
Docetaxel
9
Fulvestrant
8
Gemcitabine
7
Oxaliplatin
6
Fluorouracil
6
Pemetrexed
5
Letrozole
5
Ipilimumab
5
Cetuximab
5
spartalizumab
4
selinexor
4
dostarlimab
4
Trastuzumab
4
Irinotecan
4
trastuzumab deruxtecan
3
tisotumab vedotin
3
serabelisib
3
sacituzumab govitecan
3
ribociclib
3
olaparib
3
epacadostat
3
durvalumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Endometrial Neoplasms
×
Everolimus
×
Clear all
NCT04188548
2025-06-04
EMBER
Eli Lilly and Company
Phase 1
Active not recruiting
500 enrolled